DOCSLIB.ORG
  • Sign Up
  • Log In
  • Upload
  • Sign Up
  • Log In
  • Upload
  • Home
  • »  Tags
  • »  Mylan

Mylan

  • Responding to Mylan's Inadequate Tender Offer

    Responding to Mylan's Inadequate Tender Offer

  • Pfizer and Mylan Will Own 57% and 43% of the New Company (“Newco”), Respectively

    Pfizer and Mylan Will Own 57% and 43% of the New Company (“Newco”), Respectively

  • Mylan Signs Agreement with Gilead to Enhance Access to Tenofovir Alafenamide (TAF)- Based HIV Treatments in Developing Countries

    Mylan Signs Agreement with Gilead to Enhance Access to Tenofovir Alafenamide (TAF)- Based HIV Treatments in Developing Countries

  • Merck & Co., Inc

    Merck & Co., Inc

  • Fellow Shareholders, Since Perrigo Company

    Fellow Shareholders, Since Perrigo Company

  • 1:19-Cv-02226 Document #: 1 Filed: 04/01/19 Page 1 of 74 Pageid #:1

    1:19-Cv-02226 Document #: 1 Filed: 04/01/19 Page 1 of 74 Pageid #:1

  • Viatris Group Company Jurisdiction of Incorporation Legal Address Pfizer

    Viatris Group Company Jurisdiction of Incorporation Legal Address Pfizer

  • Chronic Hepatitis C Treatment Expansion: Generic Manufacturing

    Chronic Hepatitis C Treatment Expansion: Generic Manufacturing

  • Analysis to Aid Public Comment

    Analysis to Aid Public Comment

  • In the United States District Court for the District Of

    In the United States District Court for the District Of

  • Rxoutlook® 4Th Quarter 2020

    Rxoutlook® 4Th Quarter 2020

  • Glenmark-Answer-Mylan.Pdf

    Glenmark-Answer-Mylan.Pdf

  • Mylan and Pfizer Announce Appointment of Viatris Chief Financial Officer

    Mylan and Pfizer Announce Appointment of Viatris Chief Financial Officer

  • Pharma Asset Insights POWERED by SCRIP and in VIVO

    Pharma Asset Insights POWERED by SCRIP and in VIVO

  • Mylan Signs Exclusive Agreement with Gilead Sciences to Distribute Sovaldi® and Harvoni® in India

    Mylan Signs Exclusive Agreement with Gilead Sciences to Distribute Sovaldi® and Harvoni® in India

  • Valeant Pharms. N. Am. LLC V. Mylan Pharms. Inc., No

    Valeant Pharms. N. Am. LLC V. Mylan Pharms. Inc., No

  • ANALYSIS of AGREEMENT CONTAINING CONSENT ORDERS to AID PUBLIC COMMENT in the Matter of Mylan N.V., File No

    ANALYSIS of AGREEMENT CONTAINING CONSENT ORDERS to AID PUBLIC COMMENT in the Matter of Mylan N.V., File No

  • Mylan and Pfizer Receive Clearance from the U.S. Federal Trade Commission for Proposed Combination of Mylan and Upjohn

    Mylan and Pfizer Receive Clearance from the U.S. Federal Trade Commission for Proposed Combination of Mylan and Upjohn

Top View
  • 2015 Valeant Pharmaceuticals Annual Report
  • Mylan Sign-On Letter
  • Mylan Wins Its Amlodipine Case with Pfizer
  • 180-Day Exclusivity Under the Hatch-Waxman Amendments to The
  • Johnson & Johnson
  • Mylan and Upjohn, a Division of Pfizer, to Combine, Creating a New Champion for Global Health Uniquely Positioned to Fulfill the World’S Need for Medicine
  • FORM 10-Q Johnson & Johnson
  • Johnson & Johnson 2016 Annual Report
  • Phrma Brief on Venue
  • Case 1:15-Cv-00760-SLR Document 33 Filed 01/26/16 Page 1 of 18 Pageid #: 641
  • Filed by Mylan NV Pursuant to Rule 425
  • Mylan Provides Update on Meridian Medical Technologies', a Pfizer Company, Expanded Voluntary Worldwide Recall of Epipen® Auto-Injector
  • O:\CIVIL\Wyeth V. Mylan\Markman Hearing\Markman Order 5.Wpd
  • COUNTY of LUBBOCK Plaintiff
  • Mylan Launches Gilead Sciences' Sovaldi® Tablets in India
  • The End Is Nigh for Mylan, but How Different Will the New Company
  • Case 2:20-Cv-02065-DDC-TJJ Document 49 Filed 06/18/20 Page 1 of 15
  • 1- in the United States District Court for the Northern


© 2024 Docslib.org    Feedback